Shahram Seyedin-Noor

Shahram Seyedin-Noor is Founder and General Partner of Civilization Ventures, a venture capital firm focused on supporting cutting-edge innovations in health tech and biology. At Civilization, Shahram has invested in over 50 startups and serves on the Board of leading companies such as Rewrite Therapeutics, a gene editing innovator acquired by Intellia. Prior to founding Civilization VC, Shahram was a founding executive in several life sciences companies, including Inspirna (formerly Rgenix), a clinical-stage biotech company with first-in-class therapeutics for cancer, and NextBio, a pioneering genomics software platform acquired by Illumina. Shahram has been a pre/seed investor in category-defining startups such as Omada Health, Lemonaid Health (acquired by 23andme), Counsyl (acquired by Myriad), Bina (acquired by Roche), SingularBio (acquired by Invitae), Rocket Pharma (IPO), and Avantome (acquired by Illumina). Shahram began his career in Silicon Valley over 20 years ago and advised some of the world’s top technology leaders while at Goldman Sachs. He earned his JD from Harvard Law School and obtained a BA in Economics from Pomona College.